2-(7-chloro-6-oxoheptyl)isoindoline-1,3-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(7-chloro-6-oxoheptyl)isoindoline-1,3-dione
• 英文别名: 7-phthalimido-1-chloroheptan-2-one；2-(7-Chloro-6-oxoheptyl)isoindole-1,3-dione
• 化学式: C₁₅H₁₆ClNO₃
• 分子量: 293.75
• InChiKey: GYCIODFTXTYNRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  54.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(7-chloro-6-oxoheptyl)isoindoline-1,3-dione 、 足球烯 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 甲苯 为溶剂， 反应 0.33h， 以42%的产率得到
  参考文献：
  名称：

  Synthesis of New Methanofullerenes with Phthalimide Fragment

  摘要：

  Bromo- and chloromethyl ketones based on N-phthalyl-substituted amino acids have been synthesized via the Arndt-Eistert reaction. The products [2+1] cycloaddition to the fullerene scaffold has afforded the monoadducts of fullerene C-60.

  DOI：

  10.1134/s1070363220020139
• 作为产物：
  描述：

  6-phthalimidohexanoyl chloride 在 盐酸 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 2.0h， 生成 2-(7-chloro-6-oxoheptyl)isoindoline-1,3-dione
  参考文献：
  名称：

  Synthesis of New Methanofullerenes with Phthalimide Fragment

  摘要：

  Bromo- and chloromethyl ketones based on N-phthalyl-substituted amino acids have been synthesized via the Arndt-Eistert reaction. The products [2+1] cycloaddition to the fullerene scaffold has afforded the monoadducts of fullerene C-60.

  DOI：

  10.1134/s1070363220020139

文献信息

• Substituted guanidine derivatives, processes, pharmaceutical
  申请人：ICI Americas Inc.

  公开号：US04464374A1

  公开（公告）日：1984-08-07

  The invention relates to a guanidine derivative of the formula: ##STR1## in which W is a 2-6C alkylene chain optionally substituted by 1 or 2 1-4C alkyls; E is O, S, SO, SO.sub.2 or NR.sup.3 in which R.sup.3 is H or 1-6C alkyl; R.sup.1 is H or a straight chain 1-6C alkyl optionally substituted by 1 or 2 1-4C alkyls; or R.sup.1 and R.sup.3 are joined to form a morpholine, pyrrolidine, piperidine or piperazine ring; X, P, Y, Q and R.sup.2 are as defined in the specification, and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing process, pharmaceutical compositions and intermediates are also described. The compounds of the formula I are histamine H-2 antagonists.

  本发明涉及公式为：##STR1##的胍基衍生物，其中W是2-6C的烷基链，可选地被1或2个1-4C的烷基取代；E是O，S，SO，SO.sub.2或NR.sup.3，其中R.sup.3是H或1-6C的烷基；R.sup.1是H或一条直链1-6C的烷基，可选地被1或2个1-4C的烷基取代；或者R.sup.1和R.sup.3结合形成吗啡啶，吡咯烷，哌啶或哌嗪环；X，P，Y，Q和R.sup.2如规范中定义的，并且其药物可接受的酸加成盐。还描述了制造过程，制药组合物和中间体。公式I的化合物是组胺H-2拮抗剂。
• Guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0030092A1

  公开（公告）日：1981-06-10

  The invention relates to a guanidine of the formula:- in which R1 and R2 are H, Ci-io alkyl, C3-8 cycloalkyl or cycloalkylalkyl in which the alkyl part is C1-6 and the cycloalkyl part is C3-8, each of the alkyl, cycloalkyl and cycloalkylal- kyls being optionally substituted by one or more halogens selected from F, Cl and Br, provided that at least one of R' and R' is a halogen substituted alkyl, cycloalkyl or cycloalkyl-alkyl and provided that there is no halogen substituent on the carbon directly attached to the nitrogen; ring X is phenyl carrying 1 or 2 optional substitutents or a 5- or 6-membered heterocyclic aromatic ring containing 1, 2 or 3 hetero atoms selected from 0, N and S, which heterocyclic ring may, carry a single optional substituent selected from F, Cl, Br, I, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, trifluoromethyl, hydroxy and amino; Y is 0, S, a direct bond, methylene, vinylene, SO or NR4 in which R4 is H or C1-6 alkyl; m is 0 to 4 and n is 1 to 5, provided that when Y is 0, SO or NR4, n is 2 to 5; R3 has various significances; and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing processes and pharmaceutical compositions are also described.

  本发明涉及一种胍，其式如下：- 其中 R1 和 R2 为 H、Ci-io 烷基、C3-8 环烷基或环烷基(其中烷基部分为 C1-6，环烷基部分为 C3-8)，每个烷基、环烷基和环烷基可任选被选自 F、Cl 和 Br 的一种或多种卤素取代，条件是 R' 和 R' 中至少有一个是被卤素取代的烷基、环烷基或环烷基烷基，且与氮直接相连的碳上没有卤素取代基； 环 X 是带有 1 或 2 个任选取代基的苯基，或含有 1、2 或 3 个选自 0、N 和 S 的杂原子的 5 或 6 元杂环芳香环，该杂环可带有 1 个选自 F、Cl、Br、I、C1-6 烷基、C1-6 烷氧基、C1-6 烷硫基、三氟甲基、羟基和氨基的任选取代基； Y为0、S、直接键、亚甲基、亚乙烯基、SO或NR4，其中R4为H或C1-6烷基；m为0至4，n为1至5，但当Y为0、SO或NR4时，n为2至5；R3具有各种意义；及其药学上可接受的酸加成盐。 此外，还描述了制造工艺和药物组合物。
• Guanidine derivatives
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0045155A1

  公开（公告）日：1982-02-03

  The invention relates to a guanidine derivative of the formula: in which W is a 2-6C alkylene chain optionally substituted by 1 or 21-4C alkyls; E is O, S, SO, S02 or NR3 in which R3 is H or 1-6C alkyl; R1 is H or a straight chain 1-6C alkyl optionally substituted by 1 or 2 1-4C alkyls; or R1 and R3 are joined to form a morpholine, pyrrolidine, piperidine or piperazine; ring X, P, Y, Q and R2 are as defined in the specification, and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing process, pharmaceutical compositions and intermediates are also described. The compounds of the formula I are histamine H-2 antagonists.

  本发明涉及一种式中的胍衍生物： 其中 W 是任选被 1 个或 21 个 4C 烷基取代的 2-6C 亚烷基链；E 是 O、S、SO、S02 或 NR3，其中 R3 是 H 或 1-6C 烷基；R1 是 H 或任选被 1 个或 2 个 1-4C 烷基取代的直链 1-6C 烷基；或 R1 和 R3 连接形成吗啉、吡咯烷、哌啶或哌嗪；环 X、P、Y、Q 和 R2 如说明书中所定义，以及其药学上可接受的酸加成盐。此外，还介绍了生产工艺、药物组合物和中间体。式 I 的化合物是组胺 H-2 拮抗剂。
• US4362728A
  申请人：——

  公开号：US4362728A

  公开（公告）日：1982-12-07
• US4464374A
  申请人：——

  公开号：US4464374A

  公开（公告）日：1984-08-07